Vaccibody.com

March 23, 2017 Vaccibody AS announces vaccination of first patient in its phase IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix

Posted at 10:00h in Uncategorized

Vaccibody AS announced today vaccination of the first patient in its phase IIa study – an exploratory, open-label, multicenter study with VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). The phase I part of...

March 2, 2017 QUARTERLY REPORT – 2016 Q4

Posted at 18:14h in quarterly-reports

Q416 Quarterly report Vaccibody...

March 2, 2017 Vaccibody AS announces approval of amendment of IMPD allowing to start of expansion phase in its phase I/IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix

Posted at 18:03h in Uncategorized

Vaccibody AS announces today that inclusion of patients in the expansion phase (phase IIa) of its multicentre trial VB C-01 can be initiated as the company was informed by Paul-Ehrlich Institut („PEI“), the German regulatory authorities, that an amendment to the IMPD (Investigational Medicinal Product...

December 15, 2016 Vaccibody AS Successfully completed Private Placement of NOK 220 million (€ 24 million)

Posted at 08:00h in Uncategorized

Reference is made to the press release published by Vaccibody AS (“Vaccibody” or the “Company”) on 9 December 2016 regarding the contemplated private placement (the “Private Placement”) of new shares (the “Offer Shares”) in the Company. The Board of Directors of the Company is pleased to...

November 22, 2016 QUARTERLY REPORT- 2016 Q3

Posted at 22:58h in quarterly-reports

quarterly-report-vaccibody-2016-3q...

August 29, 2016 QUARTERLY REPORT-2016 Q2

Posted at 23:01h in quarterly-reports

quarterly-report-vaccibody-2016-q2...

August 25, 2016 Vaccibody announces positive results from the phase I part of the clinical trial VB C-01 in patients with high-grade cervical dysplasia and recommendation by the cohort review committee as well as the independent data monitoring board to continue to the expansion phase (IIa)

Posted at 11:51h in Uncategorized

Vaccibody AS today announced that the cohort review committee as well as the independent data monitoring board have completed their review of the interim analysis of the results from the phase I dosing part of the multicentre trial VB C-01. The two committees recommended continuation...

April 18, 2016 Quarterly Report – 2016 Q1

Posted at 10:13h in quarterly-reports

Quarterly report Vaccibody - 2016 Q1...

March 1, 2016 Completion of enrolment according to the study protocol for the phase I part of the VB C-01 study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix

Posted at 16:26h in Uncategorized

Vaccibody AS announced today the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...

February 1, 2016 Vaccibody awarded NOK 20 million (USD 2.3 million) to develop patient-specific therapeutic cancer vaccines

Posted at 12:28h in Uncategorized

Therapeutic vaccine company Vaccibody today announced that it has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program to develop therapeutic cancer vaccines based on each patient’s specific neoantigens. Neoantigens are tumour-...